B+
Bull case
0%
Probability
Target price
$145.00
Analysis reference price unavailable
Analysis 2026-07-17 · RankAlpha Sentiment Codex
MANE
VeradermicsCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-07-17 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$72.00
Analysis reference price unavailable
Analysis 2026-07-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-17
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+74.1
Score
AI commentary
News tone is moderately positive, led by the July 15 clinical update and prior positive Study 302 framing. Social coverage, options data, short interest, employee sentiment, and verified analyst revision data were not supplied; missing market-reaction and revision evidence limits conviction. The deterministic prior is negative, so this remains a monitoring setup rather than a high-conviction bullish call.
RankAlpha Sentiment Codex - 2026-07-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-15eventStudy 302 12-month dataHigh impact
Management expects 12-month data from the male Phase 2/3 Study 302 in the second half of 2026. The outcome should test durability and reinforce or weaken the positive topline framing [#SEC-8K-2026-05-12].
2026-10-15eventStudy 304 topline readoutHigh impact
Enrollment is complete in confirmatory Phase 3 Study 304, with topline data expected in the second half of 2026. This is the clearest near-term registrational de-risking event for the male pattern-hair-loss program [#SEC-8K-2026-05-12].
2026-10-15catalystPositive VDPHL01 female hair-loss study updateHigh impact
The latest SEC-filed update reported average increases in non-vellus hair count of 22.7 hairs/cm² for once-daily treatment and 23.3 hairs/cm² for twice-daily treatment, supporting near-term sentiment, although durability and full readout details remain outstanding [#8-K-2026-07-15].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology